Takeda Pharmaceutical President of R&D Sells $2.15M in ADSs Under 10b5-1 Plan

Transaction Overview

On September 2, 2026, Dr. Andrew Stewart Plump, Director and President of R&D at Takeda Pharmaceutical Company Limited ($TAK), disposed of 116,191 American Depositary Shares (ADSs) at a price of $18.49 per share, totaling approximately $2.15 million.

Key Details

• Security: American Depositary Shares
• Transaction Code: S (Open market sale)
• Ownership Type: Indirect (By Trust)
• Pre-Arranged Plan: The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2026.
• Remaining Holdings: Following this transaction, Dr. Plump retains indirect beneficial ownership of 145,465 ADSs held by trust, in addition to 766,569 ADSs held directly.

Significance Assessment

While the transaction represents a multi-million dollar divestment ($2.15M), the market impact is tempered because it was executed under a standard Rule 10b5-1 trading plan adopted months earlier. Dr. Plump continues to maintain substantial equity exposure with over 912,000 total ADSs remaining under direct and indirect beneficial ownership.